Harvard Medical School scientists have identified a key protein in the human immune system that drives inflammatory and ...

The eye-care company Alcon Research has entered into licensing and purchase option agreements with Potentia Pharmaceuticals to develop Potentia's leading drug candidate — a complement pathway ...

By silencing C3, investigational ARO-C3 has the potential to treat complement-mediated renal diseases by modulating the activation of the complement cascade. Pharmacodynamic effects: Maximum mean ...